Skip to search formSkip to main contentSkip to account menu

AR C124910XX

Known as: AR-C124910XX 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
2015
2015
Background. Therapy with aspirin and one of the platelet P2Y12 receptor inhibitors, preferably ticagrelor or prasugrel, is the… 
Highly Cited
2015
Highly Cited
2015
ObjectiveThe objective of this study was to assess the pharmacokinetic and pharmacodynamic behavior of ticagrelor administered… 
2012
2012
PurposeTicagrelor, a reversibly binding oral P2Y12 receptor antagonist, is predominantly metabolized by cytochrome P450 3A and… 
2012
2012
What is known and Objective:  Ticagrelor is the first reversibly binding oral P2Y12 receptor antagonist and has been approved in… 
Highly Cited
2010
Highly Cited
2010
Ticagrelor [(1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-difluorophenyl) cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d… 
Highly Cited
2010
Highly Cited
2009
Highly Cited
2009
  • R. Teng, K. Butler
  • European Journal of Clinical Pharmacology
  • 2009
  • Corpus ID: 23490203
PurposeTicagrelor (AZD6140) is the first reversibly binding oral P2Y12 receptor antagonist in development for reduction of…